Natalizumab in Recurrent, Refractory or Progressive Pulmonary Metastatic Osteosarcoma

Condition:   Pulmonary Metastatic Osteosarcoma (pOS) Intervention:   Drug: Natalizumab Sponsor:   Case Comprehensive Cancer Center Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials